BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han ZW, Lyv ZW, Cui B, Wang YY, Cheng JT, Zhang Y, Cai WQ, Zhou Y, Ma ZW, Wang XW, Peng XC, Cui SZ, Xiang Y, Yang M, Xin HW. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs 2020;38:1888-98. [PMID: 32488569 DOI: 10.1007/s10637-020-00955-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Huskey ALW, Merner ND. An investigation into the role of inherited CEACAM gene family variants and colorectal cancer risk. BMC Res Notes 2022;15:26. [PMID: 35115044 DOI: 10.1186/s13104-022-05907-6] [Reference Citation Analysis]
2 Toffoli EC, Sheikhi A, Lameris R, King LA, van Vliet A, Walcheck B, Verheul HMW, Spanholtz J, Tuynman J, de Gruijl TD, van der Vliet HJ. Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. Cancers (Basel) 2021;13:5446. [PMID: 34771609 DOI: 10.3390/cancers13215446] [Reference Citation Analysis]
3 Appleton E, Hassan J, Chan Wah Hak C, Sivamanoharan N, Wilkins A, Samson A, Ono M, Harrington KJ, Melcher A, Wennerberg E. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Front Immunol 2021;12:754436. [PMID: 34733287 DOI: 10.3389/fimmu.2021.754436] [Reference Citation Analysis]
4 Burgos M, Cavero-redondo I, Álvarez-bueno C, Galán-moya EM, Pandiella A, Amir E, Ocaña A. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis. Ther Adv Med Oncol 2022;14:175883592110726. [DOI: 10.1177/17588359211072621] [Reference Citation Analysis]
5 Aparicio C, Belver M, Enríquez L, Espeso F, Núñez L, Sánchez A, de la Fuente MÁ, González-Vallinas M. Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells. Int J Mol Sci 2021;22:11781. [PMID: 34769211 DOI: 10.3390/ijms222111781] [Reference Citation Analysis]
6 Schaft N. The Landscape of CAR-T Cell Clinical Trials against Solid Tumors-A Comprehensive Overview. Cancers (Basel) 2020;12:E2567. [PMID: 32916883 DOI: 10.3390/cancers12092567] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
7 Liao S, Wang B, Zeng R, Bao H, Chen X, Dixit R, Xing X. Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors. Drug Dev Res 2021. [PMID: 34462935 DOI: 10.1002/ddr.21870] [Reference Citation Analysis]
8 Huskey ALW, McNeely I, Merner ND. CEACAM Gene Family Mutations Associated With Inherited Breast Cancer Risk - A Comparative Oncology Approach to Discovery. Front Genet 2021;12:702889. [PMID: 34447411 DOI: 10.3389/fgene.2021.702889] [Reference Citation Analysis]
9 Mansorunov D, Apanovich N, Apanovich P, Kipkeeva F, Muzaffarova T, Kuzevanova A, Nikulin M, Malikhova O, Karpukhin A. Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis. Diagnostics (Basel) 2021;11:2370. [PMID: 34943606 DOI: 10.3390/diagnostics11122370] [Reference Citation Analysis]
10 Imami AS, O'Donovan SM, Creeden JF, Wu X, Eby H, McCullumsmith CB, Uvnäs-Moberg K, McCullumsmith RE, Andari E. Oxytocin's anti-inflammatory and proimmune functions in COVID-19: a transcriptomic signature-based approach. Physiol Genomics 2020;52:401-7. [PMID: 32809918 DOI: 10.1152/physiolgenomics.00095.2020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]